Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251693 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,038
- Enrollment target
NCT00251693 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 2,038 participants.
The verdict
NCT00251693, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,038 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Interventions
- DRUG Lansoprazole
- DRUG Dexlansoprazole MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,038 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251693
The ClinicalTrials.gov registry entry for NCT00251693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,038 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lansoprazole is the first listed.
NCT00251693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251693 about?
NCT00251693 is a clinical study titled "Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis". The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
What is the current status of trial NCT00251693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,038 participants. The study started on 2005-12. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00251693?
The interventions under investigation include: Lansoprazole (DRUG), Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00251693?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.